December 2025
1. TANG Y, Han Z, Yi X, Li J, et al
   Survival improvements and disparities in metastatic prostate adenocarcinoma, clear cell renal cell carcinoma, and urothelial carcinoma of bladder.
   Int J Cancer. 2025;157:2485-2494.
   

   >> Share

   
   October 2025
2. VLAMING M, Bleiker EMA, Schijven G, Kiemeney LALM, et al
   Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway.
   Int J Cancer. 2025 Oct 13. doi: 10.1002/ijc.70194.
   

   >> Share

   
   September 2025
3. SANTIAGO LR, Ladoukakis E, Scibior-Bentkowska D, Nedjai B, et al
   Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer.
   Int J Cancer. 2025 Sep 16. doi: 10.1002/ijc.70163.
   

   >> Share

   
   
4. CHOPRA R, Li H, Xie W, Lam DHT, et al
   Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.
   Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70149.
   

   >> Share

   
   
5. LIN E, Garmo H, Beckmann K, Bratt O, et al
   Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons.
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70133.
   

   >> Share

   
   
6. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   

   >> Share

   
   August 2025
7. HAN Y, Li C, Sun J, Wu G, et al
   Comments on "CTHRC1 promotes bone metastasis in prostate cancer".
   Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70081.
   

   >> Share

   
   July 2025
8. OKWOR UE, Raitanen J, Talala K, Tammela TLJ, et al
   Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.
   Int J Cancer. 2025 Jul 17. doi: 10.1002/ijc.70026.
   

   >> Share

   
   
9. MUCHADEYI MT, Hao S, Hernandez-Villafuerte K, Khan SA, et al
   Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.
   Int J Cancer. 2025 Jul 16. doi: 10.1002/ijc.35513.
   

   >> Share

   
   June 2025
10. STITZ R, Stoiber F, Silye R, Rebhan E, et al
    Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70019.
    

    >> Share

    
    
11. SAWADA Y, Kikugawa T, Onishi T, Arai O, et al
    CTHRC1 promotes bone metastasis in prostate cancer.
    Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70012.
    

    >> Share

    
    December 2024
12. SIECH C, de Angelis M, Jannello LMI, Di Bello F, et al
    Life expectancy in rare histological prostate cancer subtypes.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35323.
    

    >> Share

    
    
13. MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al
    Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
    Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279.
    

    >> Share

    
    October 2024
14. GRENVILLE ZS, Noor U, Rinaldi S, Gunter MJ, et al
    Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35208.
    

    >> Share

    
    September 2024
15. MOGHUL M, Tran A, Croft F, Kinsella N, et al
    The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
    Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169.
    

    >> Share

    
    July 2024
16. BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al
    Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Int J Cancer. 2024;155:314-323.
    

    >> Share

    
    June 2024
17. HUANG CY, Huang CP, Huang YY, Huang SK, et al
    Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
    Int J Cancer. 2024 Jun 26. doi: 10.1002/ijc.35040.
    

    >> Share

    
    
18. SEE AW, Conway P, Frydenberg M, Haxhimolla H, et al
    Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35052.
    

    >> Share

    
    April 2024
19. LUO Y, Yu J, Lin Z, Wang X, et al
    Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967.
    

    >> Share

    
    
20. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    

    >> Share

    
    March 2024
21. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    

    >> Share

    
    
22. LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al
    Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
    Int J Cancer. 2024;154:926-939.
    

    >> Share

    
    
23. ZHANG Y, Stopsack KH, Song M, Mucci LA, et al
    Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34898.
    

    >> Share

    
    February 2024
24. CARUANA M, Gulati R, Etzioni R, Barratt A, et al
    Benefits and harms of prostate specific antigen testing according to Australian guidelines.
    Int J Cancer. 2024;154:648-658.
    

    >> Share

    
    January 2024
25. SCHUURMAN MS, Lemmens VEPP, Portielje JEA, van der Aa MA, et al
    The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019.
    Int J Cancer. 2024;154:261-272.
    

    >> Share

    
    
26. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    

    >> Share

    
    November 2023
27. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    

    >> Share

    
    
28. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    

    >> Share

    
    
29. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    

    >> Share

    
    October 2023
30. ALMURADOVA E, Seyyar M, Arak H, Tamer F, et al
    The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share